PMID- 15840424
OWN - NLM
STAT- MEDLINE
DCOM- 20050601
LR  - 20061115
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 210
IP  - 2-3
DP  - 2005 Jun 1
TI  - Assessment of potency of allergenic activity of low molecular weight compounds 
      based on IL-1alpha and IL-18 production by a murine and human keratinocyte cell 
      line.
PG  - 95-109
AB  - Assessment of allergenic potency of low molecular weight compounds is generally 
      performed using animal models, such as the guinea pig maximisation test and the 
      murine local lymph node assay (LLNA). Progress in unravelling the mechanisms of 
      skin sensitisation, including effects on the production of cytokines by the 
      different cell types of the skin, provides us with the opportunity to develop in 
      vitro tests as an alternative to in vivo sensitisation testing. The aim of the 
      present study was to establish an in vitro method to assess the potency of 
      allergens, on the basis of their induction of cytokine production by murine and 
      human keratinocytes. In the present study we used test systems comprised of the 
      murine epidermal keratinocyte cell line HEL-30 and the human keratinocyte cell 
      line HaCaT. We exposed these cell lines to the allergens ethyl-p-aminobenzoate 
      (benzocaine), diethylamine (DEA), 2,4-dinitrochlorobenzene (DNCB), and phthalic 
      anhydride (PA). IL-1alpha and IL-18 dose-response data were evaluated by 
      non-linear regression analysis and at a stimulation index of 3 of cytokine 
      production of treatment versus control, the corresponding allergen concentration 
      was calculated. For HEL-30, for both cytokines DNCB showed the strongest potency 
      followed in this order by PA, benzocaine, and DEA. This classification was 
      similar to our previous findings obtained in the LLNA. For HaCaT, unfortunately, 
      such ranking proved to be much less feasible. In conclusion, to assess the 
      potency of allergens the murine keratinocyte cell line HEL-30 may be a useful in 
      vitro test system, alternative to in vivo models, although this requires further 
      testing using a much wider range of compounds.
FAU - Van Och, Francois M M
AU  - Van Och FM
AD  - Laboratory for Toxicology, Pathology and Genetics, National Institute for Public 
      Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The 
      Netherlands.
FAU - Van Loveren, Henk
AU  - Van Loveren H
FAU - Van Wolfswinkel, Josien C
AU  - Van Wolfswinkel JC
FAU - Machielsen, Anja J C
AU  - Machielsen AJ
FAU - Vandebriel, Rob J
AU  - Vandebriel RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - 0 (Allergens)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-18)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Allergens/immunology/*toxicity
MH  - Animals
MH  - Cell Line
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Interleukin-1/*biosynthesis/immunology
MH  - Interleukin-18/*biosynthesis/immunology
MH  - Keratinocytes/*drug effects/immunology/metabolism
MH  - Local Lymph Node Assay
MH  - Lymph Nodes/drug effects/immunology
MH  - Mice
MH  - Mice, Inbred C3H
MH  - Polymerase Chain Reaction
MH  - RNA, Messenger/biosynthesis
MH  - Regression Analysis
MH  - Species Specificity
EDAT- 2005/04/21 09:00
MHDA- 2005/06/02 09:00
CRDT- 2005/04/21 09:00
PHST- 2004/09/14 00:00 [received]
PHST- 2005/01/07 00:00 [revised]
PHST- 2005/01/10 00:00 [accepted]
PHST- 2005/04/21 09:00 [pubmed]
PHST- 2005/06/02 09:00 [medline]
PHST- 2005/04/21 09:00 [entrez]
AID - S0300-483X(05)00065-X [pii]
AID - 10.1016/j.tox.2005.01.004 [doi]
PST - ppublish
SO  - Toxicology. 2005 Jun 1;210(2-3):95-109. doi: 10.1016/j.tox.2005.01.004.